Stoke Therapeutics Profit Margin

The latest profit margin for STOK is -753.6% as of June 2026. That compares with 26.26% in the prior-year period — down 2970.2% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Stoke Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, STOK's profit margin moved from 26.26% to -753.6% — a 2970.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Stoke Therapeutics's valuation or profitability profile.

Against Healthcare companies, STOK currently prints -753.6% for profit margin, while the sector average sits near 13.89%. That is roughly 5525.4% below the sector mean. Large gaps often invite a closer look at Stoke Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Stoke Therapeutics converts resources into returns. At -753.6%, STOK may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 26.26% in the prior-year period — down 2970.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting STOK's profit margin (-753.6%), review year-over-year change from 26.26%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.